Sökning: onr:"swepub:oai:DiVA.org:uu-390191" > Circulating tumor c...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03678naa a2200325 4500 | |
001 | oai:DiVA.org:uu-390191 | |
003 | SwePub | |
008 | 190808| | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3901912 URI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a vet2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Netterberg, Ida,d 1988-u Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Uppsala University,Pharmacometrics4 aut0 (Swepub:uu)idane961 |
245 | 1 0 | a Circulating tumor cell counts is a better predictor of overall survival than dynamic tumor size changes – a quantitative modeling framework |
338 | a print2 rdacarrier | |
520 | a Purpose: Quantitative relationships between treatment-induced changes in tumor size and circulating tumor cell (CTC) counts, and their links to overall survival (OS), are lacking. We here present a population modeling framework identifying and quantifying such relationships, based on longitudinal data collected in patients with metastatic colorectal cancer (mCRC) to evaluate the value of tumor size and CTC counts as predictors of OS.Experimental design: A pharmacometric approach (i.e., population pharmacodynamic modeling) was used to characterize the changes in tumor size and CTC count and evaluate them as predictors of OS in 451 patients with mCRC treated with chemotherapy and targeted therapy in a prospectively randomized phase 3 study (CAIRO2).Results: A tumor size model of tumor quiescence and drug-resistance, was used to characterize the tumor size time-course, and was, in addition to the total normalized dose (i.e., of all administered drugs) in a given cycle, related to the CTC counts through a negative binomial model (CTC model). A CTC count≥3/7.5 mL (hazard ratio=3.51, 95% confidence interval: 2.85-4.32), as described by the CTC model, was a better predictor of OS than tumor size changes. The modeling framework was applied to explore if dose-modifications (increased and reduced) would result in a CTC count below 3/7.5 mL after 1-2 weeks of treatment.Conclusions: Time-varying CTC counts can be useful for early predicting OS in patients with mCRC, and may therefore have potential for model-based treatment individualization. Although tumor size had a strong connection to CTC, its link to OS was weaker. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng |
653 | a Farmakokinetik och läkemedelsterapi | |
653 | a Pharmacokinetics and Drug Therapy | |
700 | 1 | a Karlsson, Mats Ou Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Pharmacometrics4 aut |
700 | 1 | a Terstappen, Leon WMMu Department of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands4 aut |
700 | 1 | a Koopman, Miriamu Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands4 aut |
700 | 1 | a Punt, Cornelis JAu Department of Medical Oncology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands4 aut |
700 | 1 | a Friberg, Lena Eu Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Pharmacometrics4 aut |
710 | 2 | a Uppsala universitetb Institutionen för farmaceutisk biovetenskap4 org |
773 | 0 | t Clinical Cancer Researchx 1078-0432x 1557-3265 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-390191 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy